Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

75.97USD
29 Apr 2016
Change (% chg)

$-0.84 (-1.09%)
Prev Close
$76.81
Open
$76.70
Day's High
$76.77
Day's Low
$75.64
Volume
2,307,026
Avg. Vol
2,364,240
52-wk High
$106.84
52-wk Low
$69.89

NVS

Chart for NVS

About

Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $206,283.20
Shares Outstanding(Mil.): 2,676.99
Dividend: 2.72
Yield (%): 3.54

Financials

  NVS Industry Sector
P/E (TTM): 27.71 34.29 45.26
EPS (TTM): 2.77 -- --
ROI: 6.40 13.02 12.52
ROE: 9.07 13.71 13.41
Search Stocks

BRIEF-Novartis says Afinitor gets nod in EU for some GI, lung neuroendocrine tumors

* Novartis says afinitor recommended by chmp for european union approval to treat select gi and lung neuroendocrine tumors Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

7:52am EDT

UBS, MPM team up on $471 million cancer fund to speed drug development

(Corrects minimum commitment to $200,000 from $500,000 figure given by UBS on Wednesday)

Apr 28 2016

OFFICIAL CORRECTION-UBS, MPM team up on $471 mln cancer fund to speed drug development

ZURICH, April 27 A $471 million UBS venture fund aims to generate annual returns "north of 10 percent" for its European and Asian investors by financing new cancer drugs, helping speed them from the lab to the point where drug companies buy their rights.

Apr 28 2016

BRIEF-Novartis receives three FDA breakthrough therapy designations for Ilaris

* Novartis receives three FDA breakthrough therapy designations for Ilaris to treat rare types of periodic fever syndromes

Apr 27 2016

Novartis could refuel M&A machine with $14 billion Roche stake sale

LONDON/ZURICH Novartis is discussing options with banks for selling its near $14 billion stake in rival Roche , potentially providing cash for new deals, though a sale is not imminent, according to two people familiar with the situation.

Apr 25 2016

UPDATE 1-Novartis could refuel M&A machine with $14 bln Roche stake sale

* Novartis could use cash to buy new products (Adds analyst comment, background)

Apr 25 2016

Novartis discussing Roche stake sale, but not imminent -sources

LONDON/ZURICH, April 25 Novartis is discussing options with banks for selling its 13.5 billion Swiss franc ($13.8 billion) stake in rival Roche, though a sale is not imminent, according to two people familiar with the situation.

Apr 25 2016

Novartis to prepare the sale of its Roche stake: Sonntagszeitung

VIENNA Drugmaker Novartis aims to dispose of a 13.5 billion Swiss franc ($13.8 billion) stake in its local rival Roche and has already hired banks to support the selling process, a Swiss paper reported on Sunday.

Apr 24 2016

Novartis to prepare the sale of its Roche stake - Sonntagszeitung

VIENNA, April 24 Drugmaker Novartis aims to dispose of a 13.5 billion Swiss franc ($13.8 billion) stake in its local rival Roche and has already hired banks to support the selling process, a Swiss paper reported on Sunday.

Apr 24 2016

Novartis overcomes eyecare, heart drug pain with older drugs

ZURICH A strong performance by its older medicines helped Novartis beat profit forecasts on Thursday, making up for its struggling eyecare business and the extra costs of a poor start for a new heart failure drug.

Apr 21 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $112.08 -0.40
Pfizer Inc. (PFE.N) $32.71 -0.20
Merck & Co., Inc. (MRK.N) $54.84 -0.90
Roche Holding Ltd. (ROG.S) CHF242.50 -4.80
Roche Holding Ltd. (RO.S) CHF245.50 -2.40
Abbott Laboratories (ABT.N) $38.90 -1.52
Sanofi SA (SASY.PA) €72.11 -4.08
AstraZeneca plc (AZN.L) 3,928.00p -31.50
GlaxoSmithKline plc (GSK.L) 1,459.00p -30.00
Eli Lilly and Co (LLY.N) $75.53 -0.93

Earnings vs. Estimates

Search Stocks